Investing.com - Merck&Co (NYSE: MRK) reported second quarter EPS of $-2.06, $0.12 better than the analyst estimate of $-2.18. Revenue for the quarter came in at $15B versus the consensus estimate of $14.43B.
Guidance
Merck&Co sees FY 2023 EPS of $2.95-$3.05 versus the analyst consensus of $2.60.
Merck&Co sees FY 2023 revenue of $58.60B-$59.60B versus the analyst consensus of $53.20B.
Merck&Co's stock price closed at $106.65. It is down -9.13% in the last 3 months and up 21.73% in the last 12 months.
Merck&Co saw 0 positive EPS revisions and 18 negative EPS revisions in the last 90 days. See Merck&Co's stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co's Financial Health score is "great performance".
Check out Merck&Co's recent earnings performance, and Merck&Co's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar